BioPharma Resources

Drug Trial Radar · NCT07874282

Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer

Phase II Clinical Study to Evaluate the Efficacy and Safety of Telisotuzumab Adizutecan in Combination With RC148 as First-Line Therapy for Non-Squamous Non-Small-Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Dec 2027

Study completion Feb 2029

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To Evaluate the Safety, Tolerability, and Preliminary Antitumor Efficacy of RC148 in Combination with Telisotuzumab adizutecan as First-line Treatment for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

Conditions

  • Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology

Interventions

  • Telisotuzumab adizutecan plus RC148(ABBV-1480)Drug

    Dose1

  • Telisotuzumab adizutecan plus RC148(ABBV-1480)Drug

    Dose2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate assessed by the investigators according to RECIST v1.1Time frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital, Tongji University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.